title: Reply to IL-18 is not therapeutic for neovascular age-related macular degeneration.
authors.affiliation: Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Doyle
authors.affiliation: Ophthiris Discovery Performance Unit, GSK, Stevenage, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Adamson
authors.affiliation: Ophthalmology IPE US, RD Alternative Discovery and Development, GSK, King of Prussia, Pennsylvania, USA.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: López
authors.affiliation: Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
authors.forename: Peter
authors.initials: P
authors.lastname: Humphries
authors.affiliation: Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
authors.forename: Matthew
authors.initials: M
authors.lastname: Campbell
mesh_terms: D000818:Animals; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D020382:Interleukin-18 / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000188:drug therapy*
chemical_list: D020382:Interleukin-18